Group 1 - The FDA has informed UniQure that the data from its early-to-mid stage trial is insufficient to support a marketing application for its gene therapy aimed at treating brain disorders [1] - UniQure's gene therapy is currently under scrutiny, which may impact its future development and commercialization plans [1] Group 2 - BlackRock's Global Infrastructure Partners and EQT AB have agreed to acquire AES Corp for a total of $33.4 billion, including debt [6] - This acquisition reflects ongoing consolidation trends in the energy sector, highlighting the interest of investment firms in utility companies [6]

Company Overview - United Therapeutics announced that its experimental pill for a specific type of blood pressure disorder successfully met all primary and secondary objectives in a late-stage clinical study [1] Clinical Study Results - The late-stage study results indicate a significant advancement in treatment options for patients with this blood pressure disorder, showcasing the potential effectiveness of the new drug [1] Market Implications - The successful outcomes of the study may enhance United Therapeutics' position in the pharmaceutical market, potentially leading to increased investor interest and market valuation [1]

United Therapeutics Corp (NASDAQ:UTHR) reported better-than-expected earnings for the fourth quarter on Wednesday.The company posted quarterly earnings of $7.70 per share which beat the analyst consensus estimate of $7.09 per share. The company reported quarterly sales of $790.200 million which missed the analyst consensus estimate of $813.077 million.“As we close out another remarkable year with record total revenue for the fourth year in a row, I extend my thanks to our Unitherians whose unwavering commit ...

United Therapeutics Corp (NASDAQ:UTHR) reported better-than-expected earnings for the fourth quarter on Wednesday.The company posted quarterly earnings of $7.70 per share which beat the analyst consensus estimate of $7.09 per share. The company reported quarterly sales of $790.200 million which missed the analyst consensus estimate of $813.077 million.“As we close out another remarkable year with record total revenue for the fourth year in a row, I extend my thanks to our Unitherians whose unwavering commit ...

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?Edmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put together detailed reports of over 1,000 companies. He leads the investing group Haggerston B ...

Core Insights - United Therapeutics (UTHR) reported Q4 2025 earnings per share (EPS) of $7.70, exceeding the Zacks Consensus Estimate of $6.78, with a year-over-year increase of 24% driven by higher product sales [1][7] - The company anticipates "double-digit revenue growth" in 2026 and aims for a $4 billion annualized revenue run rate in the second half of 2027 [2][3] Financial Performance - Q4 revenues were $790.2 million, missing the Zacks Consensus Estimate of $805 million, but reflecting a 7.3% year-over-year growth, primarily from Tyvaso and Orenitram [2] - For the full year 2025, total revenues reached $3.18 billion, an 11% increase from 2024, with net earnings of $27.86 per share compared to $24.64 in 2024 [11] Product Sales Breakdown - Combined sales of Tyvaso products were $464.3 million, up 12% year over year, although they fell short of the Zacks Consensus Estimate of $488 million [4] - Tyvaso DPI generated $338.6 million in revenue, a 24% increase year over year, aided by enhanced commercialization efforts [5] - Sales of nebulized Tyvaso were $125.7 million, down 12% due to lower volumes [8] - Orenitram sales rose 12% to $121.2 million, while Remodulin sales declined 5% to $128 million, and Unituxin sales decreased 8% to $62.3 million [8] Expenses - Research and development expenses were $139.5 million, up 4.3% year over year, reflecting increased clinical development costs [9] - Selling, general, and administrative expenses rose 13.1% to $190.6 million, driven by higher consulting and personnel costs [9] Pipeline Developments - Key phase III programs include Tyvaso for chronic fibrosing interstitial lung disease and oral ralinepag for PAH [12] - The TETON-2 study showed clinical benefits in idiopathic pulmonary fibrosis patients, with management believing it could expand Tyvaso's therapeutic reach [13] - The company is also conducting the TETON-1 study and plans to meet with the FDA to expedite regulatory review if results are favorable [14] - Top-line data from the ADVANCE OUTCOMES study for ralinepag is expected in the first half of 2026 [15]

MannKind (NasdaqGM:MNKD) Q4 2025 Earnings call February 26, 2026 09:00 AM ET Company ParticipantsBrandon Folkes - Managing DirectorChris Prentiss - CFOMichael Castagna - CEORoanna Ruiz - Senior Managing DirectorConference Call ParticipantsNone - AnalystNone - AnalystOperatorGood morning, and welcome to the MannKind Corporation fourth quarter and full year 2025 financial results earnings call. As a reminder, this call is being recorded on February 26, 2026, and will be available for replay on the MannKind Co ...

MannKind (NasdaqGM:MNKD) Q4 2025 Earnings call February 26, 2026 09:00 AM ET Company ParticipantsBrandon Folkes - Managing DirectorChris Prentiss - CFOMichael Castagna - CEORoanna Ruiz - Senior Managing DirectorConference Call ParticipantsNone - AnalystNone - AnalystOperatorGood morning, and welcome to the MannKind Corporation Q4 and full year 2025 financial results earnings call. As a reminder, this call is being recorded on February 26, 2026, and will be available for replay on the MannKind Corporation we ...

MannKind (NasdaqGM:MNKD) Q4 2025 Earnings call February 26, 2026 09:00 AM ET Speaker4Good morning, and welcome to the MannKind Corporation fourth quarter and full year 2025 financial results earnings call. As a reminder, this call is being recorded on February 26, 2026, and will be available for replay on the MannKind Corporation website shortly after this call and for approximately 90 days. This call will contain forward-looking statements. Such forward-looking statements are subject to risks and uncertain ...

Core Insights - United Therapeutics Corporation reported fourth-quarter results that exceeded earnings expectations but fell short on revenue, leading to a more than 9% increase in shares intra-day [1] Financial Performance - Adjusted earnings per share for the fourth quarter were $7.70, surpassing the consensus estimate of $7.10 by $0.60 [1] - Revenue for the fourth quarter totaled $790.2 million, below expectations of $815.24 million, but represented a 7% increase from $735.9 million in the prior-year quarter [2] - Full-year 2025 revenue reached a record $3.18 billion, up 11% from 2024 [2] Product Revenue Breakdown - Total Tyvaso revenue grew 12% to $464.3 million in the fourth quarter, driven by Tyvaso DPI, which increased 24% to $338.6 million [3] - Growth in Tyvaso revenue was attributed to higher quantities sold due to continued patient expansion and increased commercial utilization linked to Medicare Part D redesign under the Inflation Reduction Act [3] - Orenitram revenue rose 12% to $121.2 million [3] Net Income and Future Outlook - Net income for the quarter reached $364.3 million, or $7.70 per diluted share, compared to $301.3 million, or $6.19 per diluted share, in the fourth quarter of 2024 [4] - For full-year 2025, net income totaled $1.33 billion, up from $1.20 billion in 2024 [4] - Management indicated that the ADVANCE OUTCOMES and TETON-1 clinical programs are expected to deliver pivotal data that could expand treatment options [4]